250 related articles for article (PubMed ID: 31902433)
1. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
[TBL] [Abstract][Full Text] [Related]
2. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
3. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
[TBL] [Abstract][Full Text] [Related]
5. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
Hougen I; Whitlock RH; Komenda P; Rigatto C; Clemens KK; Tangri N
BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34969692
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of incident oral antidiabetic drugs on kidney function.
Hung AM; Roumie CL; Greevy RA; Liu X; Grijalva CG; Murff HJ; Ikizler TA; Griffin MR
Kidney Int; 2012 Apr; 81(7):698-706. PubMed ID: 22258320
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
8. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
9. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
11. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
[TBL] [Abstract][Full Text] [Related]
12. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
13. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
16. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
17. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.
Weeda ER; Ward R; Gebregziabher M; Chandler O; Strychalski ML; Axon RN; Taber DJ
Prim Care Diabetes; 2023 Aug; 17(4):386-391. PubMed ID: 37121788
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
[TBL] [Abstract][Full Text] [Related]
20. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
